WuXi PharmaTech (NYSE: WX) Wins the 2008 Frost & Sullivan Award for Best in Class Outsourced R&D in Pharmaceuticals and Biotechnology

Friday, July 11, 2008 General News
Email Print This Page Comment bookmark
Font : A-A+

SHANGHAI, China, July 11 WuXi PharmaTech (NYSE: WX),a leading pharmaceutical, biotechnology and medical device research anddevelopment outsourcing company with operations in China and the United States,today proudly announced that it has won the 2008 Frost & Sullivan Award forBest in Class Outsourced R&D in Pharmaceuticals and Biotechnology.

(Logo: http://www.newscom.com/cgi-bin/prnh/20040705/CNM002LOGO )

Frost & Sullivan Best Practices Awards recognize companies in a variety ofregional and global markets for demonstrating outstanding achievement andsuperior performance in areas such as leadership, technological innovation,customer service, and strategic product development. The Frost & SullivanAward for Best in Class Outsourced R&D in Pharmaceuticals and Biotechnology isawarded to the company that has demonstrated commendable success in formingstrategic partnerships with global clients for outsourced laboratory andresearch manufacturing services in drug discovery and development inpharmaceuticals and biotechnology.

Quality of scientists and personnel, service portfolio, quality ofservices, speed of service delivery, cost competitiveness, past experience andreferrals are the selection criteria that Frost & Sullivan used. According toFrost & Sullivan, WuXi has excelled in the delivery of high-quality servicesin a timely manner and at competitive costs through a team of proficientscientists supported by world-class management.

"Until January, 2008, WuXi PharmaTech had provided services to more than700 global clients, with coverage of pharmaceutical, biotechnology and medicaldevices. High proportion of repeat and referral customers is a testament toits focus on customer satisfaction and operation excellence," said Frost &Sullivan Leader of China Healthcare Operation Mr. Xuchao Hou. "The maincontributing factors to this impressive reward have been exceptional leverageof China's advantage, high technical expertise and world class management,robust expanding service portfolio, adherence to strict quality control andcommitment to intellectual property rights protection."

"We are honored to receive this prestigious award in recognition of ourresearch driven, customer focus and continuous improvement practices inhelping our customers to improve the success of research and shorten the timeof development," commented Dr. Ge Li. "We will continue expanding our servicecapabilities and capacity to better serve our global pharmaceutical andmedical device customers."

About WuXi PharmaTech

WuXi PharmaTech is a leading pharmaceutical, biotechnology and medicaldevice R&D outsourcing company, with operations in China and the United States.As a research-driven and customer-focused company, WuXi PharmaTech providespharmaceutical, biotechnology and medical device companies a broad andintegrated portfolio of laboratory and manufacturing services throughout thedrug and medical device R&D process. WuXi PharmaTech's services are designedto assist its global partners in shortening the cycle and lowering the cost ofdrug and medical device R&D. For more information, please visit:http://www.wuxipharmatech.com .

About Frost & Sullivan

Frost & Sullivan, the Global Growth Consulting Company, partners withclients to accelerate their growth. The company's Growth Partnership Services,Growth Consulting and Career Best Practices empower clients to create a growthfocused culture that generates, evaluates and implements effective growthstrategies. Frost & Sullivan employs over 45 years of experience in partneringwith Global 1,000 companies, emerging businesses and the investment communityfrom more than 30 offices on six continents. For more information about Frost& Sullivan's Growth Partnerships, visit http://www.frost.com .For more information, please contact: Sherry Shao Tel: +86-21-5046-4002 Email: pr@pharmatech

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z


News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store